Prevalence of anti-SARS-CoV-2 antibody in hemodialysis facilities: a cross-sectional multicenter study from Madinah.
Ann Saudi Med
; 42(4): 246-251, 2022.
Article
in English
| MEDLINE | ID: covidwho-1988280
ABSTRACT
BACKGROUND:
Since the occurrence of coronavirus disease in 2019 (COVID-19), the global community has witnessed its exponential spread with devastating outcomes within the general population and specifically within hemodialysis patients.OBJECTIVES:
Compare the state of immunity to SARS-CoV-2 among hemodialysis patients and staff.DESIGN:
Cross-sectional study with a prospective follow-up period.SETTING:
Hemodialysis centers in Madinah region. PATIENTS ANDMETHODS:
We prospectively tested for SARS-CoV-2 antibodies in dialysis patients using dialysis centers staff as controls. The participants were tested on four occasions when feasible for the presence of anti-SARS-CoV-2 antibodies. We also analyzed factors that might be associated with seropositivity. MAIN OUTCOMEMEASURES:
SARS-CoV-2 positivity using immunoglobulin G (IgG) levels SAMPLE SIZE 830 participants, 677 patients and 153 dialysis centers staff as controls.RESULTS:
Of the total participants, 325 (257 patients and 68 staff) were positive for SARS-CoV-2 IgG antibodies, for a prevalence of 38.0% and 44.4% among patients and staff, respectively (P=.1379). Participants with a history of COVID-19 or related symptoms were more likely to have positive IgG (P<.0001). Surprisingly, positivity was also center-dependent. In a multivariable logistic regression, a history of infection and related symptoms contributed significantly to developing immunity.CONCLUSION:
The high prevalence of SARS-CoV-2 antibody among hemodialysis patients and previously asymptomatic staff suggested past asymptomatic infection. Some centers showed more immunity effects than others.LIMITATIONS:
Unable to collect four samples for each participant; limited to one urban center. CONFLICT OF INTEREST None.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Ann Saudi Med
Journal subject:
Medicine
Year:
2022
Document Type:
Article
Affiliation country:
0256-4947.2022.229
Similar
MEDLINE
...
LILACS
LIS